Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm.
BPDCN
Chemotherapy
Induction
Low-intensity
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
entrez:
28
4
2020
pubmed:
28
4
2020
medline:
9
2
2021
Statut:
ppublish
Résumé
BPDCN is ultimately a bone marrow disease requiring induction-type eradication therapy followed by hematopoietic stem cell transplant (HSCT) to achieve long-lasting remissions or cure. Various regimens have been applied to this disease with varying success. A cumulative review of the literature suggests more intense regimens have greater efficacy with acute lymphoblastic leukemia regimens preferred to acute myeloid leukemia regimens. This approach benefits fit patients who are eligible for HSCT; however, most BPDCN patients require other treatment options. The recent FDA approval of the CD123-targeted agent tagraxofusp provides a novel therapeutic alternative to traditional chemotherapy but with potential toxicities.
Identifiants
pubmed: 32336418
pii: S0889-8588(20)30022-8
doi: 10.1016/j.hoc.2020.01.011
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
539-552Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.